How Much Do Pharma Companies Spend on Doctors?
A data-driven breakdown of pharmaceutical spending on physicians — total amounts, payment categories, year-over-year trends, and which companies dominate the rankings.
Key Takeaway
In Program Year 2024, pharmaceutical and medical device companies reported $13.3 billion in payments to physicians and teaching hospitals — up from approximately $6.5 billion when the program began in 2013. Research payments account for the majority of dollars, but promotional payments (speaking fees, consulting, meals) generate the most public policy concern because of their direct link to prescribing behavior.
The $13.3 Billion Total
The CMS Open Payments program requires pharmaceutical manufacturers, biologic companies, and medical device makers to publicly disclose every payment above $10 made to a physician or teaching hospital. In Program Year 2024 — covering payments made between January 1 and December 31, 2024 — companies reported a combined $13.3 billion across millions of individual transactions.
That figure is roughly the size of a mid-cap pharmaceutical company's annual revenue. It covers everything from a $12 lunch for a primary care physician to multi-million-dollar research grants at academic medical centers. Understanding where that money flows — by category, by company, and by geography — is the core purpose of PlainPharmaWatch.
The 6,000+ companies that report payments range from global pharmaceutical giants like Pfizer and AbbVie to small device manufacturers and specialty biotech firms. Together they represent the near-totality of the US prescription drug and medical device industry. Browse all reporting companies on PlainPharmaWatch.
Spending by Payment Category
The $13.3 billion is not distributed evenly across payment types. CMS categorizes all payments into roughly a dozen buckets. The distribution matters because different categories carry different policy implications:
| Payment Category | Est. Share | Policy Concern Level |
|---|---|---|
| Research Payments | ~65–70% | Moderate — subject to IRB oversight |
| Consulting Fees | ~8–10% | High — direct promotional relationship |
| Speaking / Honoraria | ~5–8% | High — speaker bureau participation |
| Royalties & Licenses | ~4–6% | Low — IP compensation |
| Travel & Lodging | ~3–5% | Moderate — often tied to consulting |
| Food & Beverage | ~1–2% | High — small amounts, large volume |
| Education | ~1–2% | Moderate — depends on content control |
| Other Categories | ~2–5% | Varies |
Research payments dominate the totals because clinical trials are expensive and the payments are large. But the promotional categories — consulting, speaking, meals — generate the most policy concern because of their established links to prescribing behavior. A $13 lunch is a rounding error in total spending but statistically significant in its effect on brand-name prescribing. Explore all payment types in detail.
Top Spending Companies
Total payment spending is highly concentrated. A small number of large pharmaceutical companies account for a disproportionate share of all reported dollars. The top 10 companies by total payments in most recent program years share several common characteristics:
- Blockbuster drug portfolios — companies with multiple top-selling branded products have both more resources for marketing and more physicians to target.
- Active clinical pipelines — large research payments inflate total figures for companies running extensive Phase II and Phase III trials.
- Specialty therapeutic focus — oncology, immunology, diabetes, and cardiovascular companies consistently dominate because specialists in these fields have significant prescribing authority over high-cost drugs.
- Speaker bureau programs — companies that rely heavily on physician-to-physician education (a common pharma promotional tactic) generate large speaking and consulting fee totals.
PlainPharmaWatch includes detailed profiles for every company in the Open Payments database. You can sort by total payments, transaction count, number of physicians reached, or by state. Browse company profiles to see full breakdowns including payment type distributions and year-over-year comparisons.
Year-Over-Year Trends
Open Payments data goes back to 2013, providing over a decade of trend information. Several notable patterns have emerged:
Growth in Research Spending
Clinical trial spending has grown steadily as pharmaceutical R&D costs have escalated. The FDA's increasing focus on real-world evidence and post-market studies has also expanded the universe of research payments that companies must report. This growth is largely structural — it reflects the rising cost of drug development rather than increasing industry influence over physicians.
Decline in Speaker Bureau Activity
Following the opioid crisis and increased scrutiny of pharmaceutical marketing practices, many large companies reduced or eliminated their speaker bureau programs in the late 2010s. Johnson & Johnson, Allergan, and several other major companies exited the business. Reported speaking fee totals declined noticeably after 2016. Some companies have since re-entered speaker bureau programs for newer products.
Concentration in Specialty Drugs
As pharmaceutical revenue increasingly flows from high-cost specialty drugs (cancer immunotherapy, GLP-1 diabetes drugs, biologics for immune conditions), payments have concentrated in the specialists who prescribe them — oncologists, rheumatologists, endocrinologists, and neurologists. Primary care physicians have seen relatively flat or declining payment levels as industry shifts focus toward specialist audiences.
COVID-19 Impact (2020–2021)
Reported payments dropped significantly in 2020 as in-person medical conferences and office visits were suspended during the pandemic. Food and beverage payments — which typically require in-person office visits — fell sharply. Conference-related payments also declined. Total payment volumes partially recovered in 2021 and more fully by 2022–2023 as in-person industry activities resumed.
Geographic Distribution
Payments are not evenly distributed across the United States. States with large populations, major academic medical centers, and high concentrations of specialty physicians receive disproportionately large payment totals. California, New York, Texas, and Florida typically rank in the top tier by total dollars received — partly because they have large physician populations, and partly because they are home to many of the country's top academic medical centers, which attract substantial research funding.
Per-physician payment levels tell a somewhat different story. States with prestigious academic medical centers (Massachusetts, Minnesota, Maryland) often show higher per-physician averages because a relatively small number of high-paid academic physicians — running clinical trials, serving on advisory boards, and working as key opinion leaders — pull up the state average substantially. Explore state-level payment data on PlainPharmaWatch.
Putting the Numbers in Context
$13.3 billion sounds large, and it is. But it is useful to put it in context relative to other pharmaceutical industry numbers:
| Metric | Annual Estimate |
|---|---|
| US prescription drug sales | ~$550–600B |
| Total pharma industry R&D spend | ~$100–120B |
| US pharma direct-to-consumer advertising | ~$8–10B |
| Open Payments: Total reported (PY2024) | $13.3B |
| Open Payments: Research payments only | ~$8–9B est. |
| Open Payments: Promotional payments only | ~$3–4B est. |
The ~$3–4 billion in purely promotional payments represents less than 1% of US prescription drug revenues — a small fraction, but one that research suggests generates returns that far exceed the cost. A single blockbuster drug generating $5–10 billion in annual revenue provides significant financial incentive to invest in physician relationship-building, even if the per-physician payment amounts appear modest.
What Transparency Reveals
The Open Payments data is one of the most detailed windows into pharmaceutical industry marketing that exists anywhere in the world. Few countries require this level of public disclosure. The data has enabled a generation of research linking payments to prescribing, contributed to legal investigations, and allowed journalists and patient advocates to hold companies and physicians accountable.
At the same time, the data has limits. It captures what was paid but not whether the relationship was appropriate. Large research payments often represent legitimate scientific partnerships. Many consulting relationships produce genuine value. The purpose of transparency is not to presume guilt but to provide the raw information that patients, researchers, and policymakers need to evaluate the physician-industry relationship clearly.
Use PlainPharmaWatch to explore the data behind the numbers. Search companies, browse states, or view top recipients to see how the $13.3 billion breaks down in detail.
Frequently Asked Questions
How much do pharmaceutical companies spend on doctor payments each year?
In Program Year 2024, pharmaceutical and medical device companies reported $13.3 billion in payments to physicians and teaching hospitals — covering more than 6,000 companies and millions of individual transactions. This figure has grown substantially since the Open Payments program launched in 2013 with around $6.5 billion in reported transfers. The growth reflects both increased industry activity and expanded reporting requirements.
What is the largest category of pharma spending on doctors?
Research payments are consistently the largest single category — accounting for roughly 65–70% of total reported dollars in most program years. Research payments include clinical trial funding, research grants, and payments made under formal research agreements. They are structurally different from promotional payments (speaking fees, consulting fees, food) because they flow through institutional agreements and are subject to separate oversight. Consulting fees are typically the next largest category in terms of promotional spend.
Which companies spend the most on doctor payments?
Large integrated pharmaceutical companies — especially those with blockbuster drugs in competitive therapeutic areas like oncology, immunology, and diabetes — tend to top the spending rankings. Companies like AbbVie, Pfizer, Novo Nordisk, Bristol-Myers Squibb, and Eli Lilly regularly appear among the highest spenders. Research-heavy companies with active clinical pipelines also contribute large research payment totals that inflate their overall figures.
How do pharma payment levels compare to drug advertising spending?
Pharmaceutical companies spend significantly more on direct-to-consumer advertising than on individual physician payments. US pharma DTC advertising exceeded $8–9 billion annually in recent years. However, physician-directed marketing through speaking fees, consulting, and meals is considered by researchers to be more effective per dollar because it targets prescribers directly. The Open Payments data captures only the physician-directed portion of total pharma marketing spend — companies also fund medical education programs, conferences, and institutional partnerships that are not included.
Have pharma payments to doctors increased or decreased over time?
Promotional payment categories (speaking fees, consulting, food and beverage) have generally declined or plateaued over the past decade, partly in response to public scrutiny and internal company policies. Many large companies exited speaker bureau programs or reduced meal marketing following the opioid crisis. However, research-related payments have grown as companies invest in increasingly expensive late-stage clinical development. Total reported dollars have risen overall, driven primarily by research spending.
Are smaller pharma companies also required to report payments?
Yes. All applicable manufacturers — regardless of size — must report payments above the $10 per-payment or $100 aggregate annual threshold. This includes small biotech companies, generic drug makers, and specialty device manufacturers. In PY2024, over 6,000 distinct companies submitted reports. The vast majority of total dollars, however, are concentrated in a relatively small number of large companies with extensive promotional operations and clinical trial programs.
Sources
- Centers for Medicare & Medicaid Services — Open Payments Program Year 2024
- CMS Open Payments Program Year Summary Reports (2013–2024)
- IQVIA Institute — Global Use of Medicines (annual reports)
- Affordable Care Act, Section 6002 — Physician Payments Sunshine Act (2010)
- DeJong et al., "Pharmaceutical Industry–Sponsored Meals and Physician Prescribing Patterns" — JAMA Internal Medicine, 2016
- Hadland et al., "Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians with Subsequent Opioid Prescribing" — JAMA Internal Medicine, 2019
This content is for informational purposes only and does not constitute medical or legal advice. Reported payments do not imply wrongdoing or inappropriate conduct. Many physician-industry relationships are lawful and clinically beneficial. Dollar estimates for payment subcategories are approximate and based on historical CMS program year breakdowns. Always consult your healthcare provider for medical decisions.
